Patents by Inventor Jonathan William Medley

Jonathan William Medley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PD-1/PD-L1 INHIBITORS
    Publication number: 20210323922
    Abstract: Compounds according to formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Application
    Filed: November 13, 2020
    Publication date: October 21, 2021
    Applicant: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Todd Appleby, Aesop Cho, Zhimin Du, Michael Graupe, Juan A. Guerrero, Salman Y. Jabri, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Prasenjit Kumar Mukherjee, Devan Naduthambi, Gregory Notte, Eric Q. Parkhill, Barton W. Phillips, Scott Preston Simonovich, Neil H. Squires, Chandrasekar Venkataramani, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
  • SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF
    Publication number: 20210251957
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Application
    Filed: November 4, 2020
    Publication date: August 19, 2021
    Inventors: Jinfa DU, Joshua A. KAPLAN, Thorsten A. KIRSCHBERG, Tetsuya KOBAYASHI, Scott E. LAZERWITH, Rick Andrew LEE, Jonathan William MEDLEY, Michael L. MITCHELL, Philip Anthony MORGANELLI, Hyung-Jung PYUN, Sophia L. SHEVICK, Neil H. SQUIRES, William J. WATKINS
  • MCL1 INHIBITORS
    Publication number: 20210171543
    Abstract: The present disclosure generally relates to compounds of Formula (I) and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Application
    Filed: November 10, 2020
    Publication date: June 10, 2021
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, David W. Lin, Jonathan William Medley, Devan Naduthambi, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang, QingMing Zhu
  • PD-1/PD-L1 INHIBITORS
    Publication number: 20210053946
    Abstract: Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Application
    Filed: June 3, 2020
    Publication date: February 25, 2021
    Applicant: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Aesop Cho, Zhimin Du, Michael Graupe, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Prasenjit Kumar Mukherjee, Devan Naduthambi, Eric Q. Parkhill, Barton W. Phillips, Scott Preston Simonovich, Neil H. Squires, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
  • PD-1/PD-L1 INHIBITORS
    Publication number: 20210024494
    Abstract: Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Application
    Filed: July 8, 2020
    Publication date: January 28, 2021
    Inventors: Evangelos Aktoudianakis, Aesop Cho, Michael Graupe, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Devan Naduthambi, Barton W. Phillips, Scott Preston Simonovich, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
  • PD-1/PD-L1 inhibitors
    Patent number: 10899735
    Abstract: Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: January 26, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Aesop Cho, Zhimin Du, Michael Graupe, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Prasenjit Kumar Mukherjee, Devan Naduthambi, Eric Q. Parkhill, Barton W. Phillips, Scott Preston Simonovich, Neil H. Squires, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
  • Substituted pyrrolizine compounds and uses thereof
    Patent number: 10874640
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: December 29, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins
  • PD-1/PD-L1 inhibitors
    Patent number: 10774071
    Abstract: Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: September 15, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Aesop Cho, Michael Graupe, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Devan Naduthambi, Barton W. Phillips, Scott Preston Simonovich, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
  • PD-1/PD-L1 inhibitors
    Patent number: 10710986
    Abstract: Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: July 14, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Aesop Cho, Zhimin Du, Michael Graupe, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Prasenjit Kumar Mukherjee, Devan Naduthambi, Eric Q. Parkhill, Barton W. Phillips, Scott Preston Simonovich, Neil H. Squires, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
  • PD-1/PD-L1 INHIBITORS
    Publication number: 20200157094
    Abstract: Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Application
    Filed: October 22, 2019
    Publication date: May 21, 2020
    Inventors: Zhimin Du, Michael Graupe, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Eric Q. Parkhill, Barton W. Phillips, Scott P. Simonovich, Peiyuan Wang, Jie Xu, Christopher A. Ziebenhaus
  • SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF
    Publication number: 20200061024
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Application
    Filed: May 3, 2019
    Publication date: February 27, 2020
    Inventors: Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins
  • PD-1/PD-L1 INHIBITORS
    Publication number: 20200017471
    Abstract: Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Application
    Filed: July 12, 2019
    Publication date: January 16, 2020
    Inventors: Evangelos Aktoudianakis, Aesop Cho, Michael Graupe, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Devan Naduthambi, Barton W. Phillips, Scott Preston Simonovich, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
  • PD-1/PD-L1 INHIBITORS
    Publication number: 20190345131
    Abstract: Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Application
    Filed: April 18, 2019
    Publication date: November 14, 2019
    Inventors: Evangelos AKTOUDIANAKIS, Aesop CHO, Zhimin DU, Michael GRAUPE, Lateshkumar Thakorlal LAD, Paulo A. MACHICAO TELLO, Jonathan William MEDLEY, Samuel E. METOBO, Prasenjit Kumar MUKHERJEE, Devan NADUTHAMBI, Eric Q. PARKHILL, Barton W. PHILLIPS, Scott Preston SIMONOVICH, Neil H. SQUIRES, Peiyuan WANG, William J. WATKINS, Jie XU, Kin Shing YANG, Christopher Allen ZIEBENHAUS
  • PD-1/PD-L1 INHIBITORS
    Publication number: 20190270727
    Abstract: Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Application
    Filed: February 12, 2019
    Publication date: September 5, 2019
    Inventors: Evangelos Aktoudianakis, Aesop Cho, Zhimin Du, Michael Graupe, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Prasenjit Kumar Mukherjee, Devan Naduthambi, Eric Q. Parkhill, Barton W. Phillips, Scott Preston Simonovich, Neil H. Squires, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
  • Substituted pyrrolizine compounds and uses thereof
    Patent number: 10328053
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: June 25, 2019
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins
  • PD-1/PD-L1 INHIBITORS
    Publication number: 20180305315
    Abstract: Compounds according to formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Application
    Filed: April 19, 2018
    Publication date: October 25, 2018
    Inventors: Evangelos Aktoudianakis, Todd Appleby, Aesop Cho, Zhimin Du, Michael Graupe, Juan A. Guerrero, Salman Y. Jabri, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Prasenjit Kumar Mukherjee, Devan Naduthambi, Gregory Notte, Eric Q. Parkhill, Barton W. Phillips, Scott Preston Simonovich, Neil H. Squires, Chandrasekar Venkataramani, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
  • SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF
    Publication number: 20180161307
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Application
    Filed: August 25, 2017
    Publication date: June 14, 2018
    Inventors: Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins